Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching commercialization, and plenty of promising programs in its pipeline, shareholders are in for what will probably be a profitable ride, and soon.
But more importantly than that is the company's runway for growth over the long haul. Here's why investors who buy the shares soon could gain serious returns between now and the end of the decade.
At the moment, the biotech is in the final stages of bringing its first gene therapy to the market. That therapy, which it calls exa-cel, is intended to treat transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD). It was developed with the help of Vertex Pharmaceuticals. CRISPR has already submitted the appropriate materials to regulators for their consideration, and if they grant approval for both of the indications, by Q2 of 2024 it will be raking in cash and its stock will be flying.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Vertex Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 440 € für Vertex Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 422.25 €.
